CL2016003071A1 - Composiciones y métodos para tratar y prevenir infecciones por staphylococcus aureus - Google Patents

Composiciones y métodos para tratar y prevenir infecciones por staphylococcus aureus

Info

Publication number
CL2016003071A1
CL2016003071A1 CL2016003071A CL2016003071A CL2016003071A1 CL 2016003071 A1 CL2016003071 A1 CL 2016003071A1 CL 2016003071 A CL2016003071 A CL 2016003071A CL 2016003071 A CL2016003071 A CL 2016003071A CL 2016003071 A1 CL2016003071 A1 CL 2016003071A1
Authority
CL
Chile
Prior art keywords
treat
compositions
methods
staphylococcus aureus
aureus infections
Prior art date
Application number
CL2016003071A
Other languages
English (en)
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of CL2016003071A1 publication Critical patent/CL2016003071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2016003071A 2014-06-03 2016-11-29 Composiciones y métodos para tratar y prevenir infecciones por staphylococcus aureus CL2016003071A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007242P 2014-06-03 2014-06-03
US201462041423P 2014-08-25 2014-08-25
US201562115665P 2015-02-13 2015-02-13

Publications (1)

Publication Number Publication Date
CL2016003071A1 true CL2016003071A1 (es) 2017-09-15

Family

ID=54700993

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003071A CL2016003071A1 (es) 2014-06-03 2016-11-29 Composiciones y métodos para tratar y prevenir infecciones por staphylococcus aureus

Country Status (19)

Country Link
US (7) US9416172B2 (es)
EP (2) EP3970747A3 (es)
JP (5) JP6166000B1 (es)
KR (4) KR20190100471A (es)
CN (2) CN108404128A (es)
AU (2) AU2015271749B2 (es)
BR (1) BR112016028043B1 (es)
CA (1) CA2950840C (es)
CL (1) CL2016003071A1 (es)
ES (1) ES2894867T3 (es)
IL (1) IL248959B (es)
MX (2) MX394895B (es)
MY (1) MY191346A (es)
NZ (1) NZ726911A (es)
PH (2) PH12018501429B1 (es)
RU (2) RU2764981C1 (es)
SG (2) SG10201703965SA (es)
WO (1) WO2015187779A1 (es)
ZA (1) ZA201608604B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
BR112015010125A2 (pt) 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
IL315266A (en) 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
WO2019006159A1 (en) * 2017-06-30 2019-01-03 Xbiotech, Inc. COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
EP3530282A1 (en) * 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
JP7547350B2 (ja) 2019-01-22 2024-09-09 クレムソン・ユニバーシティ・リサーチ・ファウンデーション 抗エラスチン抗体及び使用方法
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
MX2021010402A (es) 2019-02-28 2021-09-14 Janssen Biotech Inc Tratamiento de la hidradenitis supurativa.
US20230235042A1 (en) 2020-04-16 2023-07-27 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
JP2023537470A (ja) 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
CN120399078B (zh) * 2025-05-08 2026-03-06 上海天泽云泰生物医药股份有限公司 靶向cd117的纳米抗体及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5077391A (en) 1989-12-01 1991-12-31 Raison Robert L Purification of immunoglobulin M
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5111074A (en) 1990-07-26 1992-05-05 Regents Of The University Of Minnesota Multi-input compound function complementary noise-immune logic
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5891438A (en) 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
EP0835880A1 (de) 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US8142780B2 (en) 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CN101074263B (zh) * 2006-05-17 2011-07-06 上海抗体药物国家工程研究中心有限公司 一种重组抗proteinA单克隆抗体及其制备方法和用途
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
EP2099932A4 (en) * 2006-12-06 2009-11-18 Repligen Corp NUCLEIC ACIDS ENCODING THE RECOMBINANT PROTEIN A
CA2722304A1 (en) 2007-04-23 2009-02-19 Sudhir Paul Immunoglobulins directed to bacterial, viral and endogeneous polypeptides
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
EP2291196A4 (en) 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
CN101339197B (zh) * 2008-07-30 2012-07-04 广州康盛生物科技有限公司 葡萄球菌蛋白a定量检测试剂盒及定量检测方法
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US9013699B2 (en) 2009-11-09 2015-04-21 Cantwell G. Carson Vaccine testing system
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
CN103687873B (zh) 2011-07-12 2016-10-19 埃克斯生物科技公司 鉴定亲和力成熟的人类抗体
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
EP2705852A1 (en) * 2012-09-06 2014-03-12 Université de Lausanne An immunogenic composition against Staphylococcus aureus comprising an inactivated recombinant non-pathogenic bacterium
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections

Also Published As

Publication number Publication date
MY191346A (en) 2022-06-17
US9783598B2 (en) 2017-10-10
US20220251175A1 (en) 2022-08-11
US20190127449A1 (en) 2019-05-02
IL248959B (en) 2022-01-01
EP3970747A2 (en) 2022-03-23
PH12016502372B1 (en) 2017-02-20
US11370831B2 (en) 2022-06-28
CN106456763B (zh) 2018-03-13
MX394895B (es) 2025-03-24
JP2017522275A (ja) 2017-08-10
US20170015734A1 (en) 2017-01-19
US9486523B2 (en) 2016-11-08
US20170349648A1 (en) 2017-12-07
JP7811143B2 (ja) 2026-02-04
IL248959A0 (en) 2017-01-31
JP2017214388A (ja) 2017-12-07
JP6672221B2 (ja) 2020-03-25
CN106456763A (zh) 2017-02-22
AU2015271749A1 (en) 2016-12-01
MX355107B (es) 2018-04-04
US20160279243A1 (en) 2016-09-29
EP3154584A1 (en) 2017-04-19
KR20170007825A (ko) 2017-01-20
KR101753553B1 (ko) 2017-07-03
RU2764981C1 (ru) 2022-01-24
BR112016028043B1 (pt) 2023-12-12
US11773157B2 (en) 2023-10-03
JP2022105178A (ja) 2022-07-12
JP2020073548A (ja) 2020-05-14
AU2018200886A1 (en) 2018-02-22
US10577410B2 (en) 2020-03-03
US10214581B2 (en) 2019-02-26
SG10201703965SA (en) 2017-06-29
JP6166000B1 (ja) 2017-07-19
AU2018200886B2 (en) 2019-06-06
CN108404128A (zh) 2018-08-17
KR102015451B1 (ko) 2019-08-28
RU2636780C1 (ru) 2017-11-28
AU2015271749B2 (en) 2018-03-01
EP3970747A3 (en) 2022-10-05
BR112016028043A2 (pt) 2017-10-24
JP2024119907A (ja) 2024-09-03
PH12016502372A1 (en) 2017-02-20
EP3154584B1 (en) 2021-08-04
NZ764692A (en) 2024-07-26
US9416172B2 (en) 2016-08-16
EP3154584A4 (en) 2018-06-06
ZA201608604B (en) 2018-05-30
CA2950840A1 (en) 2015-12-10
NZ726911A (en) 2023-01-27
WO2015187779A1 (en) 2015-12-10
US20150344548A1 (en) 2015-12-03
KR20210047355A (ko) 2021-04-29
PH12018501429A1 (en) 2019-02-27
KR20170078846A (ko) 2017-07-07
SG11201609487QA (en) 2016-12-29
KR20190100471A (ko) 2019-08-28
ES2894867T3 (es) 2022-02-16
US20200131252A1 (en) 2020-04-30
PH12018501429B1 (en) 2022-04-27
CA2950840C (en) 2023-09-26
MX2016015812A (es) 2017-04-25

Similar Documents

Publication Publication Date Title
CL2016003071A1 (es) Composiciones y métodos para tratar y prevenir infecciones por staphylococcus aureus
EP3236978C0 (en) An antimicrobial composition
PT3355990T (pt) Compostos semifluorados e as suas composições
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
BR112016026699A2 (pt) Métodos para tratar infecções micobacterianas não tuberculosas pulmonares
BR112016024191A2 (pt) composições e aplicações agrícolas utilizando compostos minerais
EP3500102C0 (en) ANTIMICROBIAL COMPOSITION
EP3375108A4 (en) SELECTIVE WIFI
PT3393468T (pt) Métodos para tratar imunodeficiências
EP3443078A4 (en) ANTIMICROBIAL COMPOSITIONS
EP3458041A4 (en) ANTIBACTERIAL COMPOSITIONS
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina
DK3451829T3 (da) Antimikrobielle sammensætninger
BR112017011076A2 (pt) métodos e composições para prevenir ou reduzir infecções de plantas cultivadas por agentes patogênicos fúngicos e bacterianos
BR112016018442A2 (pt) agentes antibacterianos
PL3016663T3 (pl) Sterylizowana kompozycja termożelowalna
FR3020948B1 (fr) Composition antimicrobienne
EP3397289A4 (en) ANTIMICROBIAL WIPE CLOTH
BR112016021875A2 (pt) composição tópica
EP3420820A4 (en) ANTIMICROBIAL COMPOSITION
FR3025106B1 (fr) Composition antimicrobienne
DK3233104T3 (da) Immunterapi-behandlinger og -sammensætninger
DK3174396T3 (da) Synergistisk antimikrobiel sammensætning
IL252707A0 (en) Compositions and methods for treating diseases and conditions
EP3310363A4 (en) ANTIMICROBIAL FORMULATIONS